MyCME brings secondary topics up

Most CME websites focus solely on the primary specialty: you register as a PCP or cardiologist, you see online activities that are applicable to you.

But what if you're an internist, 90% of whose practice focuses on diabetes, yet you have an interest in gastroenterology or women's health? Or a family doctor who has a focus in hem/onc?

To address these learners, Haymarket Medical Education is taking the wraps off a totally redesigned MyCME.com portal this month.

It marks the first revamp of HME's online hub for accessing CME since its inception in 2009. With the site, set to go live September 6, HME aimed for a modern med-ed interface.

“We were looking to try to find a way to make the site more in-tune with the clinicians of today,” said Kenny Cox, VP, myCME. That is, “a site that could create a more personalized and more relevant educational experience.”

Upon registering, clinicians who visit the site will be shown activities that are applicable to not just their primary specialty but to their secondary specialty as well.

“It's really driven [by a need to] make it easier for people to find the CME they're looking for,” said Cox.

The next iteration is slated for  2014. HME is a sister company to Haymarket Media, owner of MM&M, but operates independently.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.